April 24, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial
 

Tokyo, Jan 7, 2013 (JCN) - Takara Bio and its collaborators, University of Pennsylvania and Drexel University College of Medicine have initiated a Phase 1 clinical trial in its program for HIV-1 infections.

Takara Bio has developed an investigational retroviral technology for HIV-1 gene therapy, in which MazF, an endoribonuclease from Escherichia coli, confers resistance to a broad-spectrum of HIV-1 strains on CD4+ T cells.

The Regulatory Sponsor of this study is Carl H. June, M.D., Professor of Pathology and Laboratory Medicine at the University of Pennsylvania. The Principal Investigator of the study is Jeffrey M. Jacobson, M.D., Chief of the Division of Infectious Diseases and HIV Medicine and Professor of Medicine, Microbiology and Immunology Division at Drexel University College of Medicine.

The MazF retroviral vector for this study is manufactured at the GMP compliant Center for Cell and Gene Therapy Facility of Takara Bio (Kusatsu, Shiga, Japan). The patients' CD4+ T cells will be modified with MazF retroviral vector at the GMP compliant Cell and Vaccine Production Facility at the University of Pennsylvania.

In this clinical trial, the patients will be monitored for safety, tolerability and immunogenicity of the autologous CD4+ T cells modified with the MazF endoribonuclease for six months. The estimated total enrollment is twelve subjects, six in each of the Cohorts 1 and 2.

By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Takara Bio  News  
  Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy  (Apr 10, 2014)
  Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America  (July 26, 2013)
  Takara Bio launches Nippi's iMatrix-511 Worldwide  (July 12, 2013)
  Takara Bio Grants Cellular Dynamics a Commercial License to Use RetroNectin for iPSC Production  (June 24, 2013)
  Takara Bio Licenses Mushroom Production Technology to Sun Toward Tech  (June 13, 2013)
  Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial  (Jan 7, 2013)
  Takara Bio Submits IND Application for HIV-1 Gene Therapy to the FDA  (Mar 23, 2012)
  Takara Bio and Tianjin Medical University in Gene Therapy Project  (Aug 3, 2011)
  Takara Bio RetroNectin to UCLA for TCR-gene Therapy Clinical Trials in Advanced Melanoma  (Dec 18, 2008)
  Takara Bio Announces Start of Clinical Research of Cancer Immunotherapy using RetroNectin(R) Expansion Culture System at Tianjin Cancer Institute & Hospital, China  (May 2, 2008)



 Recent  Medical News   
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)
Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America (July 26, 2013)
Takara Bio launches Nippi's iMatrix-511 Worldwide (July 12, 2013)
Furukawa Electric Develops Quartz Dot Test Kit to Detect Acanthamoeba (July 10, 2013)

More Medical news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)